Maviret and Vosevi were highly effective and well tolerated in clinical trials.

Scientists have slammed a review of hep C research that suggests that curing the virus does not extend life or reduce liver-related disease.

A clinic in Baltimore showed great success in eradicating hep C among a traditionally challenging population.

The risk is higher for hemorrhagic stroke, which entails bleeding in the brain.

More treatment options may soon become available for those with hepatocellular carcinoma (HCC), which is often diagnosed late.

The complications include liver cancer, failure, transplantation or death. Consistent medical monitoring is recommended.

The fixed-dose combination tablet sofosbuvir/velpatasvir/voxilaprevir provides a good alternative to those who have failed treatment.

In a study of people treated for hep C, having liver cancer at the time was the most prominent factor associated with failing therapy.

Few recontracted the virus after being cured, and some of those who got reinfected spontaneously cleared it.

A study found that young people treated with biologic drugs for inflammatory bowel disease or various rheumatologic conditions were at risk.